FATE News and Press, Fate Therapeutics Inc. From 04/22/21

Cathie Wood is betting on a genomic revolution because she believes it will be the next big industry disrupting development. We believe Wood’s favorite stocks, Vertex Pharmaceuticals Incorporated (VRTX) and Incyte Corporation (INCY), have attractive upside potential and are ideal inves...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. Short review of IDNA. For further details see: Healthcare Dashboard For April And Focus On IDNA

Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus. Their lead asset, tebentafusp, i...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. From 1/2/2016 to to-date, investing in all 50 stocks, equally weighted, would have produced a total return of 185.8%, an active ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...

The Nasdaq 100 has had an absolutely wild year. Over the past 12 months, the blue chip tech index returned an astonishing 68% to investors. Among the best performers of the index are companies with the most innovative products or services. Shares of Sea Limited ...

Fate Therapeutics (FATE) announced that after his 12-years tenure Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the company that he is retiring as of June 30, 2021.Bob Valamehr, Ph.D., Chief Research and Development Officer and scientific leader of the compa...

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Of...

Stephen Mandel’s 13F portfolio value increased ~19% from $23.20B to $27.51B. The number of positions increased from 32 to 41. Lone Pine Capital increased MercadoLibre and DexCom while dropping PayPal and Capital One Financial. The top three positions are Shopify, Coupa Soft...

Fate Therapeutics, an immuno-oncology biopharmaceutical company, has novel core technology with the potential to become a strong competitor in the sector. The company's iPSC-based NK-cell and T-cell immunotherapies are at the forefront of innovation in one of science's most cutting-ed...